Genetic Analysis
Genetic Analysis AS is a diagnostic company focused on unlocking the potential of the human microbiome through its proprietary GA-map® technology platform. A key achievement is the commercialization of the world's first CE-marked IVD test for gut dysbiosis in IBS and IBD, which has been used in over 50 clinical trials. The company is strategically expanding its product portfolio with research-use assays like the MHI GutHealth test, developed with Ferring Pharmaceuticals, and pursuing opportunities in companion diagnostics to support pharmaceutical development.
Private Company
Total funding raised: $11M
AI Company Overview
Genetic Analysis AS is a diagnostic company focused on unlocking the potential of the human microbiome through its proprietary GA-map® technology platform. A key achievement is the commercialization of the world's first CE-marked IVD test for gut dysbiosis in IBS and IBD, which has been used in over 50 clinical trials. The company is strategically expanding its product portfolio with research-use assays like the MHI GutHealth test, developed with Ferring Pharmaceuticals, and pursuing opportunities in companion diagnostics to support pharmaceutical development.
Technology Platform
The GA-map® platform is a proprietary, probe-based multiplex technology for simultaneous analysis of numerous bacterial targets in stool, coupled with a validated software algorithm that delivers standardized, interpretable results without external bioinformatics.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
GA competes with large diagnostic labs, direct-to-consumer microbiome testing companies, and sequencing service providers. Its main differentiation is its focus on clinical-grade, standardized, and regulatory-cleared IVD tests for the healthcare and pharmaceutical markets, rather than consumer wellness insights.